SynCore Biotechnology Co., Ltd. (4192) Stock Price & Analysis
4192 Stock Chart & Stats
- Day’s Range
- TWD 15.30 - TWD 16.15
- 52-Week Range
- TWD 15.30 - TWD 27.00
- Previous Close
- TWD 16.60
- Volume
- N/A
- Average Volume (3M)
- 12.40K
- Market Cap
- TWD 541.63M
- Enterprise Value
- TWD 571.78M
- Total Cash (Recent Filing)
- TWD 145.80M
- Total Debt (Recent Filing)
- TWD 12.53M
- Price to Earnings (P/E)
- ―
- Beta
- 0.42
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
4192 FAQ
What was SynCore Biotechnology Co., Ltd.’s price range in the past 12 months?
What is SynCore Biotechnology Co., Ltd.’s market cap?
When is SynCore Biotechnology Co., Ltd.’s upcoming earnings report date?
How were SynCore Biotechnology Co., Ltd.’s earnings last quarter?
Is SynCore Biotechnology Co., Ltd. overvalued?
Does SynCore Biotechnology Co., Ltd. pay dividends?
What is SynCore Biotechnology Co., Ltd.’s EPS estimate?
How many shares outstanding does SynCore Biotechnology Co., Ltd. have?
What happened to SynCore Biotechnology Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of SynCore Biotechnology Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
SynCore Biotechnology Co., Ltd.
SynCore Biotechnology Co.,Ltd, a Taiwan-based enterprise, specializes in the development and commercialization of biotechnology services, alongside offering expertise in food advisory and medicine inspection. The company's robust pipeline includes several promising drug candidates. Among its novel chemical entities (NCEs), SB01 is an injectable anti-cancer compound currently undergoing Phase II clinical trials for head and neck cancer. Another anti-cancer NCE, SB02, is in preclinical development, targeting stomach cancer. Beyond novel compounds, SynCore also markets established pharmaceutical solutions. This includes SB03-Veregen, an ointment prescribed for external genital and perianal warts. Its portfolio further extends to SB04, a conventional medication for age-related macular degeneration, presently in Phase II clinical studies. Additionally, SynCore is advancing SB05-EndoTAG, an established drug undergoing Phase III clinical trials for the treatment of both pancreatic cancer and triple-negative breast cancer. In a related venture, the company distributes epiCam brand cameras, which are designed for recording the progression of ophthalmic diseases. SynCore maintains strategic collaborations with notable entities such as Medigene AG, MacuCLEAR Inc., Sinphar Pharmaceutical Co., Ltd., and The National Health Research Institutes. Founded in 2008, SynCore Biotechnology Co.,Ltd is headquartered in Yilan City, Taiwan, and operates as a subsidiary of Sinphar Pharmaceutical Co., Ltd.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Chih-Wen Lee
- Employees
- 40
- Website
- www.syncorebio.com
- Address
- 84 Chung Shan Road, Yilan City, TP, 269, TW
SynCore Biotechnology Co., Ltd. (4192) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |

